Movement Alert｜PHARMARON Rises 3.61% in Regular Trading, CRO Sector Broadly Strengthens as AI Drug Discovery Catalyst Persists

Market Focus09-18

On September 18, PHARMARON rose 3.61% in regular trading, trading at HK$30.38/share, with turnover of HK$54.47 million. The rally was driven by continued strength across the CRO sector, further fueled by Novo Nordisk's partnership with Anthropic to leverage its Claude Science platform for new drug development.

On the industry front, China's innovative drug out-licensing deal value has surpassed US$120 billion in total, bolstering R&D budgets for pharmaceutical companies and pushing CRO order backlogs into a phase of both volume and pricing growth. Goldman Sachs previously affirmed a clear recovery trajectory for China's CRO/CDMO industry and assigned PHARMARON a Buy rating, while Daiwa, Bank of America, and Morgan Stanley raised target prices to HK$38.5, HK$38.4, and HK$35.6, respectively. Within the Life Sciences Tools & Services sector, INSILICO surged 11.16%, XTALPI gained 8.85%, GENSCRIPT BIO rose 7.25%, WUXI APPTEC climbed 3.84%, and WUXI BIO added 2.99%, reflecting broad sector momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117560882?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-18 09:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117560882","market":"hk","top_or_hot":-1,"title":"Movement Alert｜PHARMARON Rises 3.61% in Regular Trading, CRO Sector Broadly Strengthens as AI Drug Discovery Catalyst Persists","media":"Market Focus","content":"<p><p>On September 18, PHARMARON rose 3.61% in regular trading, trading at HK$30.38/share, with turnover of HK$54.47 million. The rally was driven by continued strength across the CRO sector, further fueled by Novo Nordisk's partnership with Anthropic to leverage its Claude Science platform for new drug development.</p><p>On the industry front, China's innovative drug out-licensing deal value has surpassed US$120 billion in total, bolstering R&D budgets for pharmaceutical companies and pushing CRO order backlogs into a phase of both volume and pricing growth. Goldman Sachs previously affirmed a clear recovery trajectory for China's CRO/CDMO industry and assigned PHARMARON a Buy rating, while Daiwa, Bank of America, and Morgan Stanley raised target prices to HK$38.5, HK$38.4, and HK$35.6, respectively. Within the Life Sciences Tools & Services sector, INSILICO surged 11.16%, XTALPI gained 8.85%, GENSCRIPT BIO rose 7.25%, WUXI APPTEC climbed 3.84%, and WUXI BIO added 2.99%, reflecting broad sector momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PHARMARON Rises 3.61% in Regular Trading, CRO Sector Broadly Strengthens as AI Drug Discovery Catalyst Persists</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PHARMARON Rises 3.61% in Regular Trading, CRO Sector Broadly Strengthens as AI Drug Discovery Catalyst Persists\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-18 09:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 18, PHARMARON rose 3.61% in regular trading, trading at HK$30.38/share, with turnover of HK$54.47 million. The rally was driven by continued strength across the CRO sector, further fueled by Novo Nordisk's partnership with Anthropic to leverage its Claude Science platform for new drug development.</p><p>On the industry front, China's innovative drug out-licensing deal value has surpassed US$120 billion in total, bolstering R&D budgets for pharmaceutical companies and pushing CRO order backlogs into a phase of both volume and pricing growth. Goldman Sachs previously affirmed a clear recovery trajectory for China's CRO/CDMO industry and assigned PHARMARON a Buy rating, while Daiwa, Bank of America, and Morgan Stanley raised target prices to HK$38.5, HK$38.4, and HK$35.6, respectively. Within the Life Sciences Tools & Services sector, INSILICO surged 11.16%, XTALPI gained 8.85%, GENSCRIPT BIO rose 7.25%, WUXI APPTEC climbed 3.84%, and WUXI BIO added 2.99%, reflecting broad sector momentum.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1117560882","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117560882","pubTimestamp":1789696701,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 18, PHARMARON rose 3.61% in regular trading, trading at HK$30.38/share, with turnover of HK$54.47 million. The rally was driven by continued strength across the CRO sector, further...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势提醒|康龙化成常规交易上涨3.61%，人工智能药物发现催化剂持续，CRO板块普遍走强","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On September 18, PHARMARON rose 3.61% in regular trading, trading at HK$30.38/share, with turnover of HK$54.47 million. The rally was driven by continued strength across the CRO sector, further fueled by Novo Nordisk's partnership with Anthropic to leverage its Claude Science platform for new drug development.On the industry front, China's innovative drug out-licensing deal value has surpassed US$120 billion in total, bolstering R&D budgets for pharmaceutical companies and pushing CRO order backlogs into a phase of both volume and pricing growth. Goldman Sachs previously affirmed a clear recovery trajectory for China's CRO/CDMO industry and assigned PHARMARON a Buy rating, while Daiwa, Bank of America, and Morgan Stanley raised target prices to HK$38.5, HK$38.4, and HK$35.6, respectively. Within the Life Sciences Tools & Services sector, INSILICO surged 11.16%, XTALPI gained 8.85%, GENSCRIPT BIO rose 7.25%, WUXI APPTEC climbed 3.84%, and WUXI BIO added 2.99%, reflecting broad sector momentum.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117560882","isCrawlerRequest":true}